奥希替尼联合化疗对比单药治疗EGFR合并TP53突变晚期NSCLC的随机临床试验
这项多中心、随机、开放标签、3期研究在中国17家中心纳入294例EGFR敏感突变合并TP53突变的初治IV期或复发非鳞NSCLC患者,1:1随机接受奥希替尼联合化疗或奥希替尼单药治疗。主要终点为研究者评估的无进展生存期,联合组中位PFS显著延长(34.0 vs 15.6个月;HR 0.44,95%CI 0.32-0.60;
要点
- EGFR合并TP53突变晚期NSCLC一线奥希替尼联合化疗较单药显著延长PFS(34.0 vs 15.6个月)。
- 联合治疗获益在预设亚组中一致,包括脑转移和L858R突变患者。
- 总生存数据尚不成熟(成熟度30.6%),但观察到联合治疗获益趋势。
核心结论
- 在EGFR突变合并TP53突变的晚期NSCLC患者中,一线奥希替尼联合化疗较奥希替尼单药显著延长无进展生存期。
研究设计与样本
- 多中心、随机、开放标签、3期研究,在中国17家中心开展。
- 2021年3月25日至2024年7月11日共纳入294例初治IV期或复发非鳞NSCLC、携带TP53和EGFR敏感突变的患者。
- 患者1:1随机接受奥希替尼联合化疗(培美曲塞和卡铂每3周4周期,随后奥希替尼联合培美曲塞维持;n=146)或奥希替尼单药(n=148)。
- 主要终点为研究者评估的无进展生存期;次要终点包括总生存期、缓解、安全性和生活质量。
主要发现
- 中位年龄57岁(范围26-79岁),女性159例(54.1%)。
- 数据截止日期为2025年11月11日;联合组中位随访25.1个月,单药组26.1个月。
- PFS获益在预设亚组中一致,包括脑转移和L858R突变患者。
- 总生存数据尚不成熟(成熟度30.6%),但观察到联合治疗的总生存获益趋势。
关键数值与推荐
- 联合组≥3级治疗相关不良事件发生率高于单药组,未发现新的安全性信号。
临床怎么用
- 对于EGFR敏感突变合并TP53突变的晚期NSCLC患者,一线可考虑奥希替尼联合化疗以提高无进展生存期。
- 联合治疗需关注≥3级治疗相关不良事件的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Combination therapy has emerged as a promising therapeutic approach for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, its clinical benefit-risk profile remains a focus of ongoing debate. Identifying patients most likely to derive benefit from such regimens remains an unmet clinical need. OBJECTIVE: To prospectively compare the efficacy and safety of first-line osimertinib plus chemotherapy with osimertinib monotherapy for patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized, open-label, phase 3 study conducted at 17 sites in China. Between March 25, 2021, and July 11, 2024, a total of 294 eligible patients with treatment-naive, stage IV or recurrent nonsquamous NSCLC harboring concurrent TP53 and EGFR-sensitizing mutations were enrolled. INTERVENTIONS: Patients were randomized (1:1) to receive osimertinib plus chemotherapy (pemetrexed and carboplatin every 3 weeks for 4 cycles, followed by maintenance therapy of osimertinib plus pemetrexed; n = 146) or osimertinib monotherapy (n = 148). MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, response, safety, and quality of life. RESULTS: Among 294 enrolled patients, the median age was 57 years (range, 26-79 years), and 159 (54.1%) were female. The data cutoff date was November 11, 2025. At a median follow-up of 25.1 months for the osimertinib-chemotherapy group and 26.1 months for the osimertinib monotherapy group, median progression-free survival was significantly longer with osimertinib plus chemotherapy than with osimertinib monotherapy (34.0 vs 15.6 months; difference, 18.4 months [95% CI, 9.9-22.3]; hazard ratio, 0.44 [95% CI, 0.32-0.60]; P < .001). This benefit was consistent across prespecified subgroups, including those with brain metastases and L858R mutations. The overall survival data remained immature (30.6% maturity); however, a trend toward overall survival benefit with combination therapy was observed. The incidence of grade 3 or higher treatment-related adverse events was higher in the combination group, with no new safety signal identified. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, osimertinib plus chemotherapy significantly increased progression-free survival among patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations. These findings provided a clinical rationale for individualized combination strategies in the management of patients with EGFR-mutated NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04695925.
引用
- Zhou T, Zhou H, Gao F, et al. Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA. 2026. PMID: 42574006. doi:10.1001/jama.2026.10599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。